EN DE
Watch InventisBio Co. Ltd. A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

InventisBio Co. Ltd. A (688382) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of InventisBio Co. Ltd. A stock ¥7.76, price ¥11.71, that is 33.7% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100005Q22

IC InventisBio Co. Ltd. A logo Thin data Nov 16, 2026

InventisBio Co. Ltd. A

688382 · SHG

Expensive (fair value 34% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Quality 40/100 
Fair value ¥7.76 · Overvalued 
Falling price (downtrend) 
Weak Growth (revenue YoY −77.9 %/yr in CNY) 
Negative free cash flow 
Trails peers (2/7) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch InventisBio Co. Ltd. A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥47.90 ¥6.72 Fair Value ¥7.76 Jul 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

52‑month range ¥6.72 – ¥47.90 · fair‑value band ¥5.82 – ¥9.70 · the ¥11.71 price screens above the ¥7.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow InventisBio Co. Ltd. A in your weekly email

Every Wednesday you see whether InventisBio Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China.

Show moreShow less

Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer; Taragarestrant (D-0502), which is in phase III and II to treat estrogen receptor positive/human epidermal growth factor receptor 2-breast cancer.

The company also develops D"2570, which is in phase III, II, and I clinical trials, as well as preclinical trials to treat autoimmune disease; and Darbinurad (D-0120), which is in phase II clinical trial to treat gout.

In addition, it is developing YF087 which is in preclinical trial to treat MSI-high solid tumors; YF550 which is in preclinical trial to treat chromosome instability solid tumors; and YF057 which is in preclinical trial to treat atopic dermatitis and asthma.

InventisBio Co., Limited was founded in 2013 and is based in Shanghai, China.

Stock analysis

InventisBio Co. Ltd. A (688382) currently trades at ¥11.71, while our estimate is ¥7.76, 34% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ¥5.82 (bear) to ¥9.70 (bull), the price of ¥11.71 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

InventisBio Co. Ltd. A reported revenue of 37.3M CNY in FY2025 versus 0 CNY in FY2021. Reported net income was −317M CNY in FY2025.

Key figures

Market cap 7.0B CNY (≈ $1.1B) Small · EPS (TTM) ¥−0.5900 · Return on equity −21.4% · Return on assets (EBIT) −22.9% (5-year average) · Operating margin −940% · Revenue (TTM) 71.4M CNY · Revenue growth (YoY) −1.8% · Free cash flow −162M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 65% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −34%, 688382 screens richer than that median.

Fair Value

Bear ¥5.82 Fair Value ¥7.76 Bull ¥9.70
Price ¥11.71 · Downside -33.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 3
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 69
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 79
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

688382 screens overvalued: fair value 34% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare InventisBio Co. Ltd. A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Below median
Fair Value upside −33.7% · Below median
Profitability
Return on assets −18.6% · Above median
Growth and dividend
Revenue growth (quarter YoY) −1.8% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.58× · Pricier than median
P/S (12 months) 98.40× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 688382
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 688382
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs 688382
argenx SE ARGX $950.95 $908.40 −4% vs 688382
CSL Limited CSL A$199.55 A$186.49 −7% vs 688382
Moderna, Inc MRNA $215.27 $135.64 −37% vs 688382
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs 688382
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 688382
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs 688382
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 688382

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

InventisBio Co. Ltd. A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "InventisBio Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688382

Frequently asked questions

Is InventisBio Co. Ltd. A (688382) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is ¥7.76 versus a price of ¥11.71, about 34% lower (overvalued).
What is the fair value of 688382?
Our estimate for InventisBio Co. Ltd. A is ¥7.76 (as of Nov 16, 2026), built from audited fundamentals. The current price: ¥11.71.
What is the quality score of 688382?
InventisBio Co. Ltd. A has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for InventisBio Co. Ltd. A (688382)?
Our calculated price target is the estimate of ¥7.76 (as of Nov 16, 2026). Cautious scenario ¥5.82, optimistic scenario ¥9.70. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the InventisBio Co. Ltd. A stock forecast for 2026?
Our estimate puts fair value at ¥7.76, about 34% lower versus a price of ¥11.71 (overvalued). Cautious scenario ¥5.82, optimistic scenario ¥9.70. The calculation is refreshed regularly with new filings.
What is the revenue of InventisBio Co. Ltd. A (688382)?
InventisBio Co. Ltd. A reported trailing-twelve-month revenue of about 71.4M CNY (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of InventisBio Co. Ltd. A (688382)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For InventisBio Co. Ltd. A it is ¥7.76 per share (as of Nov 16, 2026), against a price of ¥11.71.
Is InventisBio Co. Ltd. A stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 688382 trades above its calculated fair value: price ¥11.71, fair value ¥7.76, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688382?
No. The price is what the market pays today (¥11.71); the fair value is what the company's own numbers justify (¥7.76). For InventisBio Co. Ltd. A the two are ¥3.95 per share apart. That gap is exactly why we show both numbers side by side.
How much is InventisBio Co. Ltd. A worth?
The market values InventisBio Co. Ltd. A at about 7.0B CNY (market capitalisation, as of Nov 16, 2026). Per share that is ¥11.71; our models calculate a fair value of ¥7.76 per share.
What do the bullish and bearish scenarios say about 688382?
Our models span a range for InventisBio Co. Ltd. A: cautious scenario ¥5.82, base ¥7.76, optimistic ¥9.70 per share (as of Nov 16, 2026, price ¥11.71). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of InventisBio Co. Ltd. A (688382)?
Balance-sheet figures for InventisBio Co. Ltd. A (as of Nov 16, 2026): return on equity −21.4%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 688382 from its 52-week high?
InventisBio Co. Ltd. A trades at ¥11.71, about 65% below its 52-week high of ¥33.40 and at the low of ¥11.71 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of ¥7.76 is for.
Which stocks are comparable to InventisBio Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is InventisBio Co. Ltd. A stock attractive at the current price?
The data as of Nov 16, 2026: price ¥11.71, calculated fair value ¥7.76 (−34%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. InventisBio Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of InventisBio Co. Ltd. A (688382)?
The closing price on Nov 17, 2026 was ¥11.71. Our estimate is ¥7.76, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with InventisBio Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥9.70). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of InventisBio Co. Ltd. A

How large is the market capitalisation of InventisBio Co. Ltd. A (688382)?
The market capitalisation of InventisBio Co. Ltd. A is 7.0B CNY (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of InventisBio Co. Ltd. A (688382)?
Earnings per share at InventisBio Co. Ltd. A are ¥−0.5900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of InventisBio Co. Ltd. A (688382)?
The return on equity (ROE) of InventisBio Co. Ltd. A is −21.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of InventisBio Co. Ltd. A (688382)?
On an EBIT basis the return on assets of InventisBio Co. Ltd. A is −22.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of InventisBio Co. Ltd. A (688382)?
The operating margin of InventisBio Co. Ltd. A is −940% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at InventisBio Co. Ltd. A (688382)?
Revenue at InventisBio Co. Ltd. A is down 1.8% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does InventisBio Co. Ltd. A (688382) generate?
The free cash flow of InventisBio Co. Ltd. A is −162M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch InventisBio Co. Ltd. A in the live analysis

One click puts InventisBio Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.